ANATOMY OF ARTIFICIAL HAPPINESS: NEUROBIOLOGICAL LIMITS OF PHARMACOLOGICAL MIMICRY

Abstract

Despite the expanding arsenal of psychopharmacology, achieving sustainable patient well-being remains a challenge. The reductionist approach of equating happiness with neurotransmitter concentrations encourages misguided attempts to chemically induce positive affect, while ignoring the evolutionary mechanisms of brain adaptation. Materials and Methods. A bibliosemantic analysis of the literature was conducted, focusing on the neuroanatomy of reward systems, the theory of allostasis, and the molecular mechanisms of action of psychoactive substances. Results. The analysis of the obtained data demonstrates that the brain functions as a complex prediction system, where emotions act not as ends in themselves, but as signals of “Reward Prediction Error”. It has been demonstrated that pharmacological agents (opioids, psychostimulants) cause intense but non-physiological receptor stimulation without the corresponding behavioral and semantic context. This leads to a dissociation between the processes of “wanting” (a dopamine-dependent process) and “liking” (an opioid-dependent process). It has been established that direct chemical stimulation inevitably activates homeostatic and allostatic counter-regulatory mechanisms (opponentprocess theory). A key role in this is played by the hyperactivation of the lateral habenula (the “disappointment center”) and the dynorphin/kappa-opioid receptor system, which inhibit dopamine release and induce dysphoria to restore equilibrium. Conclusions. Pharmacology is incapable of generating authentic happiness due to the lack of contextual validation of the chemical signal. Its role is permissive, not generative: restoring neuroplasticity and reducing stress create a biological foundation for natural emotional regulation through real-life experience, rather than replacing it.